MAP
KROS icon

Madison Avenue Partners’s Keros Therapeutics KROS Stock Holding History

Madison Avenue Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.7M Hold
626,583
– – 0.29% 24
2026
Q1 		$6.92M Sell
626,583
-197,124
-24% -$3.04M 0.3% 24
2025
Q4 		$16.8M Sell
823,707
-1,884,511
-70% -$33.1M 0.72% 19
2025
Q3 		$42.8M Buy
2,708,218
+16,753
+0.6% +$247K 2.56% 13
2025
Q2 		$35.9M Buy
+2,691,465
New +$36.3M 2.4% 13

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Madison Avenue Partners's KROS Position: Q2 2026 in Review

Madison Avenue Partners held its Keros Therapeutics (KROS) position steady in Q2 2026 at 626,583 shares worth $6.7M. The position accounts for 0.29% of the portfolio, ranked #24.

Madison Avenue Partners first reported a position in KROS in Q2 2025 and has held it in 5 quarters since. The position peaked at $42.8M in Q3 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Madison Avenue Partners held 626,583 shares of Keros Therapeutics worth $6.7M as of Q2 2026.
  • Madison Avenue Partners left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up 0.29% of Madison Avenue Partners's portfolio in Q2 2026, its #24 holding.
  • Madison Avenue Partners first reported a position in Keros Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Madison Avenue Partners's Keros Therapeutics position peaked at $42.8M in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Madison Avenue Partners's 13F filing for Q2 2026, filed 14 Aug 2026.